Teodor Gottfried

Ramat Gan, TA 52621, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.

Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 16, 2022

Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.

Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.

Journal: Thoracic cancer

Published: January 03, 2022

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer.

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer.

Journal: Cancers

Published: April 08, 2021

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2020

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers.

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers.

Journal: Frontiers in oncology

Published: November 03, 2020

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.

Journal: Frontiers in oncology

Published: September 05, 2020

Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling.

Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling.

Journal: Translational lung cancer research

Published: July 18, 2020

Immunotherapy response modeling by ex-vivo organ culture for lung cancer.

Immunotherapy response modeling by ex-vivo organ culture for lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: July 13, 2020

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.

Journal: International journal of cancer

Published: April 23, 2020

Self-reported sleep quality as prognostic for survival in lung cancer patients.

Self-reported sleep quality as prognostic for survival in lung cancer patients.

Journal: Cancer management and research

Published: October 16, 2019

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.

Journal: Cancer management and research

Published: April 02, 2019

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 21, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026